Hospital-Acquired Infections Market size over 2023-2032 can be credited to the rise in cosmetic surgeries amid the gradual ease of COVID-19 restrictions. Surgery is considered a risk factor for hospital-acquired bacterial infections, with the lack of hygiene protocols increasing the vulnerability to surgical site infections.
Based on a 2022 survey conducted by the American Society of Plastic Surgeons, nearly 30% of plastic surgery clinics doubled their businesses compared to pre-pandemic levels. The acceleration in aesthetic-focused practices is expected to boost the diagnosis of hospital-acquired infections and add impetus to market development over the foreseeable future.
Healthcare-associated infections occur while patients are receiving treatment at healthcare facilities, including hospitals, surgical centers, and ambulatory clinics. These infections can impact the lungs, bloodstream, skin, digestive tract, and urinary tract. Methicillin-resistant Staphylococcus Aureus infections, for example, develop when germs enter the bloodstream through a medical tube or catheter inserted into the vein.
The lack of basic hygiene services in healthcare facilities and the growing geriatric population are among the prominent reasons behind the hospital-acquired infections market expansion. As per the WHO’s report, between 2015 and 2050, the proportion of the global population aged 60 years or above will nearly double from 12% to 22%. The rate of hospitalization will therefore increase since elder people are susceptible to chronic diseases. These factors, along with the mounting investment to revitalize and strengthen public health infrastructures, will bolster the need for hospital-acquired infection treatment.
Hospital-acquired infections industry size from the urinary tract infection segment will witness a major upsurge between 2023 and 2032, given the escalating number of elective surgeries across private hospitals. Since catheters are required for bedbound patients after surgical procedures, the prevalence of urinary tract infections is projected to grow. Likewise, the high incidence of urinary incontinence among adult women will drive the implementation of hospital-acquired infection control strategies to limit urinary tract infections across healthcare settings.
The antifungal treatment segment is set to hold a considerable share of the hospital-acquired infections market over the forthcoming years, considering the rise in the fungal disease burden, especially in Europe. As per a study published in Eurosurveillance, between 2019 and 2021, five European nations including France, Italy, and Germany documented 14 outbreaks of the Candida Auris fungus, posing a serious health threat. The COVID-19 outbreak has also led to a surge in multidrug-resistant organisms, posing a concern for hospitalized patients with weakened immune systems. These factors will augment the adoption of antifungal treatment for COVID-19-impacted patients.
On the regional front, the Asia Pacific hospital-acquired infections industry value is set to expand substantially by 2032, on account of the high chronic disease burden. Based on data from the World Heart Foundation, cardiovascular disease accounts for around one-third of death cases in Southeast Asia. Such factors will result in more hospitalizations due to non-communicable diseases and drive the rate of HAIs.
Pfizer, Abbott, Bristol Myers Squibb, GSK plc (formerly GlaxoSmithKline), Eli Lilly and Company, Cipla, Bayer, Merck, Daiichi Sankyo, Johnson & Johnson, F. Hoffmann-La Roche, Cepheid (Danaher Corporation), and AstraZeneca are some of the key players in the hospital-acquired infections market. These companies are focusing on innovative treatment launches, partnerships, and acquisitions to reinforce their footprint in the global industry.